Meet the New Oral GLP-1 Pill That Matches Ozempic: 12.1% Weight Loss in 36 Weeks

Chicago, MMN Correspondent: What if one of the most powerful tools for weight loss came in the form of a simple daily pill? Researchers say that future is closer than ever. A new oral GLP-1 drug called aleniglipron has just shown impressive results in a randomized phase II trial, helping people lose up to 12.1% of their starting weight in 36 weeks. The findings were published in Nature Medicine and are generating excitement among doctors, patients, and public health experts. The trial involved 230 adults with an average age of 50, recruited from 38 U.S. medical centers. Participants were randomly assigned to receive either a placebo or one of three daily doses of aleniglipron: 45 milligrams, 90 milligrams, or 120 milligrams. After 36 weeks, the results showed a clear dose response. People taking 45 mg lost an average of 9.0% of their baseline weight. Those on 90 mg lost 10.7%. The 120 mg group reached 12.1%. The placebo group had a negligible change of only 0.5%. These numbers are particularly meaningful because they sit right alongside the weight loss seen with injectable GLP-1 receptor agonists, which typically range from 10% to 15% over similar time periods. What makes aleniglipron so interesting is its structure. Current GLP-1 drugs like semaglutide are peptide based molecules that require injection. They are large, complex, and expensive to manufacture. Aleniglipron is a small molecule. That means it can be made through standard chemical synthesis, similar to aspirin or blood pressure medications. It is taken by mouth, with or without food, and does not need refrigeration. This convenience could remove many of the practical barriers that keep people from starting or continuing injectable therapies. Dr. Robert Kushner, professor emeritus of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine at Northwestern University and a co-author of the study, emphasized the versatility of this approach. 'The difference with aleniglipron is it's a small molecule, which means it's chemically made and could be taken with or without food. Most medications we take, whether it's aspirin or blood pressure medicine, are small molecules. They're chemicals that you make structurally, and because of that you can potentially combine them with other medications,' he said. That flexibility could open the door to combination pills, where aleniglipron works alongside other treatments to address multiple health conditions at once. How does the drug work? Aleniglipron mimics GLP-1, a naturally produced hormone that helps regulate glucose metabolism and appetite. Once in the body, it prompts insulin release after meals, slows down gastric emptying, and sends fullness signals to the brain. The combined effect is a steady decrease in caloric intake and consistent weight reduction. Because it works orally, patients can take it at home without injection training or repeated clinic visits. Safety data from the trial looked reassuring. Gastrointestinal side effects were the most common and included nausea, diarrhea, and vomiting. These were generally mild to moderate and tended to become less frequent over time. About 10.4% of participants stopped treatment due to side effects, but the researchers found no cases of drug induced liver injury. That last point matters, because liver toxicity has been a concern for some other oral GLP-1 candidates. Aleniglipron is not the only oral option moving through the pipeline. Another small molecule, orforglipron, has also generated strong weight loss results in clinical trials. Some studies have reported liver signals at higher doses, making that drug a bit more complicated to develop. Aleniglipron did not show such signals during this phase II trial, which could give it an edge as the race toward an oral GLP-1 treatment continues. The demand for easier obesity treatments is hard to overstate. The World Health Organization notes that global obesity rates have nearly tripled since 1975, and excess weight is now a leading risk factor for type 2 diabetes, cardiovascular disease, and certain cancers. A daily pill could make effective treatment available to a much wider audience, especially in countries where cold-chain storage and injectable supplies are not always available. Production scale is another advantage. Peptide-based medications are created through complex biological processes that take time and money. Small-molecule drugs can be synthesized in large quantities using established chemical methods. This could lower costs and improve access worldwide. The shift from injection to pill might be one of the most practical advances in metabolic medicine in years. The research team is already planning the next stage. A phase III trial will be larger and longer, and should confirm these results while refining the dosing schedule. As Dr. Kushner explained, 'We didn't find any concerns; no new safety signals. We found a dose that seems to be effective, and the dose escalation will be slowed down further as we go into phase III trial to increase tolerability.' That measured approach is exactly how durable solutions are built. There are natural limitations to keep in mind. The 36-week study is short in the grand scheme of a chronic condition like obesity. Long-term effectiveness, weight maintenance, and cardiovascular outcomes will need more investigation. The study population also leaned heavily toward white participants and included more women than men, so future trials will need broader representation. Even with those caveats, the arrival of a drug like aleniglipron is a meaningful step. For millions of people who would benefit from losing weight but hesitate at the idea of injections, a once-daily pill changes the conversation. It shifts the focus from access and convenience to science and results. If the phase III data hold up, this small-molecule approach could bring effective obesity care to more people in more places than ever before.